Completed PHASE2 INTERVENTIONAL 3-arm NCT01517698

A Study of RO4917523 in Patients With Fragile X Syndrome

A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.

Sponsor: Hoffmann-La Roche

Conditions Fragile X Syndrome

Interventions Placebo RO4917523 0.5 mg RO4917523 1.5 mg

Updated 9 times since 2017 Last updated: Jul 6, 2016 Started: May 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fragile X Syndrome, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Oct 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Aurora, United States , Bahía Blanca, Argentina , Baltimore, United States , Belfast, United Kingdom , Bordeaux, France , Brampton, Canada , Bron, France , Caba, Argentina , Chicago, United States and 38 more locations